Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.43 |
| ▸ | TUBB | P07437 | 3/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.43 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364192 | 1.00 | HDAC4 (0.53) | HDAC4HDAC2HDAC8ERN1ALDH1A1 | |
| SCHEMBL4579619 | 0.79 | HDAC4 (0.53) | HDAC4HDAC2HDAC8ERN1ALDH1A1 | |
| SCHEMBL29788008 | 0.79 | HDAC4 (0.53) | HDAC4HDAC2HDAC8ERN1ALDH1A1 | |
| SCHEMBL2044179 | 0.77 | CA1 (0.51) | ERN1NPC1RAB9ALMNAMAPT | |
| SCHEMBL29788180 | 0.77 | CA1 (0.51) | ERN1NPC1RAB9ALMNAMAPT | |
| SCHEMBL6769062 | 0.77 | ERN1 (0.48) | HDAC4HDAC2HDAC8ERN1ALDH1A1 | |
| SCHEMBL642228 | 0.77 | HDAC4 (0.58) | HDAC4HDAC2HDAC8ERN1ALDH1A1 | |
| SCHEMBL29868499 | 0.76 | KDM4E (0.56) | ERN1KDM4EMAPTHSD17B10 | |
| SCHEMBL6773146 | 0.76 | KDM4E (0.56) | ERN1KDM4EMAPTHSD17B10 | |
| SCHEMBL7260001 | 0.76 | ERN1 (0.49) | HDAC4HDAC2HDAC8ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121233-A1 | Synthesis and Characterization of Second Generation Benzofuranone Ring Substituted Noscapine Analogs | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8426398-B2 | Conjugates of noscapine and folic acid and their use in treating cancer | EMORY UNIVERSITY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110286919-A1 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER | EMORY UNIVERSITY (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2010083104-A2 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER | EMORY UNIVERSITY (US) | 2010-07-22 | — | — | WO | disclosed |
| US-6673814-B2 | CONTROLLED-RELEASE BY IMPLANTABLE DEVICES, DELIVERY PUMPS, WAFERS, AND BIODEGRADABLE POLYMERS | EMORY UNIVERSITY | 2004-01-06 | — | — | US | disclosed |
| US-20020137762-A1 | Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents | EMORY UNIVERSITY | 2002-09-26 | — | — | US | disclosed |
| US-6376516-B1 | FOR TREATING NEOPLASTIC CANCERS INCLUDING COLON, LUNG, BRAIN, OVARIAN, PROSTATE, BREAST, AND BLADDER CANCER AND LEUKEMIA; LOW TOXICITY | EMORY UNIVERSITY | 2002-04-23 | — | — | US | disclosed |
| WO-1999008528-A1 | NOSCAPINE DERIVATIVES, USEFUL AS ANTICANCER AGENTS | EMORY UNIVERSITY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137762-A1 | Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents | NOS1, NOS2, HCCS | HDAC4 1246/4885HDAC2 1778/4885HDAC8 1850/4885 |
| US-20140121233-A1 | Synthesis and Characterization of Second Generation Benzofuranone Ring Substituted Noscapine Analogs | MAP2, MAP4, TUBB1 | HDAC4 269/4885HDAC2 618/4885HDAC8 556/4885 |
| US-20110286919-A1 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER | FOLR1, FOLR2, DHFR | HDAC4 4199/4885HDAC2 4468/4885HDAC8 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.